KRAS G12C
Clinical trials for KRAS G12C explained in plain language.
Never miss a new study
Get alerted when new KRAS G12C trials appear
Sign up with your email to follow new studies for KRAS G12C, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for KRAS lung cancer: first human trial launches
Disease control Recruiting nowThis early-stage study tests a new drug called BBO-8520 in people with advanced non-small cell lung cancer that has a specific genetic change (KRAS G12C). The main goals are to check the drug's safety and see if it can shrink tumors. About 350 adults will take part, and the drug …
Matched conditions: KRAS G12C
Phase: PHASE1 • Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) • Aim: Disease control
Last updated May 26, 2026 07:26 UTC
-
New combo attack on lung cancer brain tumors shows promise in early trial
Disease control Recruiting nowThis study tests whether combining a targeted drug (adagrasib) with precise radiation (stereotactic radiosurgery) can better control brain metastases in people with a specific type of lung cancer (KRAS G12C-mutated NSCLC). About 30 adults with untreated brain tumors will receive …
Matched conditions: KRAS G12C
Phase: PHASE2 • Sponsor: Ryan Gentzler, MD • Aim: Disease control
Last updated May 26, 2026 07:23 UTC
-
New immunotherapy option for pancreatic cancer patients with no other choices
Disease control AVAILABLEThis program provides early access to an experimental immunotherapy called ELI-002 7P for people with a specific type of pancreatic cancer (KRAS/NRAS-mutated) who have had their tumor removed but are at high risk of the cancer coming back. It is for patients who have no other tre…
Matched conditions: KRAS G12C
Sponsor: Elicio Therapeutics • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
New drug targets Hard-to-Treat KRAS cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called BBO-11818 in people with advanced solid tumors (lung, pancreatic, colorectal, or others) that have a specific KRAS gene mutation. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Abo…
Matched conditions: KRAS G12C
Phase: PHASE1 • Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) • Aim: Disease control
Last updated May 20, 2026 11:58 UTC
-
New hope for rare blood vessel disorders: targeted drugs enter trial
Disease control Recruiting nowThis study tests two targeted drugs for people with vascular malformations (abnormal blood or lymph vessels). Participants with slow-flow malformations and a specific gene mutation receive alpelisib, while those with fast-flow malformations and another mutation receive mirdametin…
Matched conditions: KRAS G12C
Phase: PHASE2 • Sponsor: Murdoch Childrens Research Institute • Aim: Disease control
Last updated May 19, 2026 12:00 UTC
-
New targeted drug hopes to shrink Hard-to-Treat cancers
Disease control Recruiting nowThis study tests an experimental drug called FMC-376 in people with advanced solid tumors that have a specific genetic change (KRAS G12C). The goal is to find a safe dose and see if the drug can shrink tumors. About 400 adults whose cancer has worsened after standard treatments w…
Matched conditions: KRAS G12C
Phase: PHASE1, PHASE2 • Sponsor: Frontier Medicines Corporation • Aim: Disease control
Last updated May 18, 2026 12:10 UTC